| 丙型肝炎治疗新药替拉瑞韦 |
| |
| 引用本文： | 王莹莹,龚 莉,王成港,王春龙. 丙型肝炎治疗新药替拉瑞韦[J]. 医学教育探索, 2011, 34(6): 482-486 |
| |
| 作者姓名： | 王莹莹 龚 莉 王成港 王春龙 |
| |
| 作者单位： | 1.天津中医药大学，天津 300193 2.释药技术与药代动力学国家重点实验室，天津 300193 3.天津药物研究院，天津 300193 |
| |
| 摘 要： | 丙型肝炎病毒（hepatitis C virus，HCV）是一种高度变异的正链RNA黄病毒，具有慢性转化率高、病变率高等特征。有研究表明，NS3/NS4A多功能蛋白酶是HCV复制所必须的，因而NS3/NS4A蛋白酶抑制剂在HCV治疗中的意义备受关注。替拉瑞韦（Telaprevir）是一种可逆的HCV NS3/NS4A蛋白酶抑制剂，动物试验和临床试验都表明它可以有效地直接攻击HCV并阻断其复制，对HCV的抑制作用持久，将成为丙型肝炎病毒的新型治疗药物。
|
| 关 键 词： | 替拉瑞韦；丙型肝炎病毒；NS3/NS4A蛋白酶；蛋白酶抑制剂；1型丙型肝炎 |
Telaprevir used for treatment of hepatitis C |
| |
| WANG Ying-ying,GONG Li,WANG Cheng-gang,WANG Chun-long. Telaprevir used for treatment of hepatitis C[J]. Researches in Medical Education, 2011, 34(6): 482-486 |
| |
| Authors: | WANG Ying-ying GONG Li WANG Cheng-gang WANG Chun-long |
| |
| Affiliation: | 1.Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China 2.State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin 300193, China 3.Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China |
| |
| Abstract: | Hepatitis C virus (HCV) is a highly variable positive-strand RNA flavivirus, and has the characteristics of chronic high conversion and pathologic change. There are evidences shown that NS3/NS4A protease activity is essential for viral replication, thus the therapeutic significance of inhibiting the HCV protease NS3/NS4A has been widely concerned. Telaprevir, an ig administered, reversible, and peptidomimetic inhibitor of the HCV protease NS3/NS4A, has been proved to be effective for attacking HCV and breaking viral replication both in animal experiments and clinical trials. It is expected to become a new drug for treatment of HCV. |
| |
| Keywords: | Telaprevir hepatitis C virus (HCV) NS3/NS4A protease protease inhibitor hepatitis C 1 |
|
| 点击此处可从《医学教育探索》浏览原始摘要信息 |
|
点击此处可从《医学教育探索》下载全文 |
